| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| AZN | Astrazeneca PLC | $37.56 | $95.16B | N/A |
Top Stock Reports for Visa, JPMorgan & Bank of America
http://www.zacks.com/research-daily/777118/top-stock-reports-for-visa-jpmorgan-bank-of-america?cid=CS-ZC-FT-research_daily-777118
Feb 21, 2020 - Top Stock Reports for Visa, JPMorgan & Bank of America
0
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
http://www.zacks.com/stock/news/777121/pharma-stock-roundup-azn-reports-q4-results-nvs-pfe-drugs-get-eu-approval?cid=CS-ZC-FT-analyst_blog|stock_roundup-777121
Feb 21, 2020 - AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
0
Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review
http://www.zacks.com/stock/news/775823/roches-tecentriq-sbla-for-lung-cancer-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-775823
Feb 20, 2020 - Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.
0
AstraZeneca's (AZN) CEO Pascal Soriot on Q4 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4324488-astrazenecas-azn-ceo-pascal-soriot-on-q4-2019-results-earnings-call-transcript?source=feed_sector_healthcare
Feb 14, 2020 - AstraZeneca PLC (NYSE:AZN) Q4 2019 Earnings Conference Call February 14, 2020 7:00 AM ET Company Participants Pascal Soriot – Chief Executive Officer Dave Fredrickson – Executive Vice President, Oncol
0
AstraZeneca PLC (AZN) Q4 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2020/02/14/astrazeneca-plc-azn-q4-2019-earnings-call-transcri.aspx?source=iedfolrf0000001
Feb 14, 2020 - AZN earnings call for the period ending December 31, 2019.
0
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study
http://www.zacks.com/stock/news/763946/mercks-keytruda-meets-pfs-endpoint-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-763946
Feb 13, 2020 - Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
0
FibroGen's Anemia Drug Goes to FDA for Review
https://www.fool.com/investing/2020/02/12/fibrogens-anemia-drug-goes-to-fda-for-review.aspx?source=iedfolrf0000001
Feb 12, 2020 - A decision on Roxadustat should arrive by Dec. 20.
0
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
http://www.zacks.com/stock/news/761981/fibrogens-fgen-nda-for-roxadustat-accepted-by-the-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-761981
Feb 12, 2020 - The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
0
What's in Store for AstraZeneca (AZN) This Earnings Season?
http://www.zacks.com/stock/news/760054/whats-in-store-for-astrazeneca-azn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-760054
Feb 11, 2020 - AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.
0
What's in Store for Ironwood (IRWD) This Earnings Season?
http://www.zacks.com/stock/news/758462/whats-in-store-for-ironwood-irwd-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-758462
Feb 10, 2020 - Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
0
Page 1>